

## Drug Monograph

Drug/Drug **Adzenys<sup>®</sup> XR(amphetamine) extended release orally**  
 Class: **disintegrating tablet/ ADHD**  
 Prepared for: MO HealthNet  
 Prepared by: Xerox Heritage, LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

<b>Purpose:</b>	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
<b>Dosage Forms:</b>	Adzenys <sup>®</sup> XR is an extended release orally disintegrating tablet containing 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, or 18.8 mg of amphetamine respectively.	
<b>Manufacturer:</b>	Neos Therapeutics LP, Grand Prairie, TX 750501`	
<b>Indications:</b>	Adzenys <sup>®</sup> XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder in patients 6 years and older.	
<b>Costs:</b>	\$9 per tablet of each strength of Adzenys <sup>®</sup> XR. Wholesale Acquisition Cost	
<b>Summary of Findings:</b>	The Division recommends adding this drug to the current ADHD clinical edit.	
<b>Status Recommendation:</b>	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Fiscal Edit	<input type="checkbox"/> Open Access <input checked="" type="checkbox"/> Clinical Edit
<b>Type of PA Criteria:</b>	<input type="checkbox"/> Increased Risk of ADE <input checked="" type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Under Solicitation <input type="checkbox"/> No PA Required

Prepared By: Luke Boehmer, Pharm.D.  
 Date: May 31, 2016